Verve Therapeutics Inc

Verve Therapeutics Inc is an American biotechnology company primarily engaged in the development of single-course, in vivo, liver-directed gene editing medicines aimed at effectively treating cardiovascular disease. Established in 2018, the firm has its headquarters in Cambridge, Massachusetts, and serves clients across the USA and the world. The firm has developed a number of strategic partnerships and collaborations with various influential industry leaders, including the Broad Institute, Harvard University and Acuitas Therapeutics, Inc. The firm is listed on the NASDAQ under the ticker VERV. Track this instrument by adding it to your eToro watchlist and get instant updates on VERV price changes.